1
|
Yimpak P, Tantiworawit A, Rattanathammethee T, Angsuchawan S, Laowatthanapong S, Tasuya W, Bumroongkit K. Alteration of SF3B1 and SRSF2 Genes in Myelodysplastic
Syndromes Patients in Upper Northern Thailand. Asian Pac J Cancer Prev 2019; 20:1215-1221. [PMID: 31030497 PMCID: PMC6948884 DOI: 10.31557/apjcp.2019.20.4.1215] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
Background: The frequency and pattern of mutation in SF3B1 and SRSF2 RNA splicing machinery genes were found to vary among myelodysplastic syndrome (MDS) patients in different populations. There have been less reports of incidence of these gene mutations in Thailand especially in upper northern Thailand. This study therefore had aims to investigate the frequency and pattern of mutation in mutational hotspot of SF3B1 and SRSF2 genes among MDS patients in upper northern Thailand and to investigate the clinical features associated with the mutations. Methods: Fifty-five MDS patients who underwent treatment at Maharaj Nakorn Chiang Mai Hospital participated in this study. The detection of SF3B1 and SRSF2 hotspot mutations was carried out using polymerase chain reaction followed by Sanger sequencing. In addition, clinical features of individual patients with these gene mutations were also investigated. Results: SF3B1 mutations (SF3B1mut) were found in 9 patients (16.4%) including E622D (1/9), R625C (1/9), H662Q (1/9), K700E (5/9), and Q699H co-mutation with K700E (1/9). SRSF2 mutations (SRSF2mut) were found in 4 patients (7.3%) which included P95H (3/4) and P95L (1/4). The SF3B1mut was associated with lower hemoglobin levels (p = 0.023) and higher platelet counts (p = 0.047) when compared with MDS patients without SF3B1mut, while SRSF2mut tended to occur in patients with a higher percentage of bone marrow blasts (p = 0.074). Conclusion: The findings confirmed the difference in frequency of SF3B1 and SRSF2 mutations among different populations. Specifically, we found a co-mutation of Q699H and K700E that has not been previously reported in MDS patients in the COSMIC database. It was also found that SF3B1mut was strongly associated with low hemoglobin level, and high platelet counts whereas SRSF2mut was mostly clustered in MDS with excess blasts subsequently increasing the probability of progression to acute myeloid leukemia.
Collapse
Affiliation(s)
- Phuttirak Yimpak
- Department of Anatomy, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
| | - Adisak Tantiworawit
- Division of Hematology, Department of Internal Medicine , Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
| | - Thanawat Rattanathammethee
- Division of Hematology, Department of Internal Medicine , Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
| | - Sirinda Angsuchawan
- Department of Anatomy, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
| | - Sikrai Laowatthanapong
- Department of Anatomy, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
| | - Witoon Tasuya
- Department of Anatomy, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
| | - Kanokkan Bumroongkit
- Department of Anatomy, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
| |
Collapse
|
2
|
Iwai K, Yaguchi M, Nishimura K, Yamamoto Y, Tamura T, Nakata D, Dairiki R, Kawakita Y, Mizojiri R, Ito Y, Asano M, Maezaki H, Nakayama Y, Kaishima M, Hayashi K, Teratani M, Miyakawa S, Iwatani M, Miyamoto M, Klein MG, Lane W, Snell G, Tjhen R, He X, Pulukuri S, Nomura T. Anti-tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC-dependent vulnerability. EMBO Mol Med 2019; 10:emmm.201708289. [PMID: 29769258 PMCID: PMC5991599 DOI: 10.15252/emmm.201708289] [Citation(s) in RCA: 46] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
The modulation of pre-mRNA splicing is proposed as an attractive anti-neoplastic strategy, especially for the cancers that exhibit aberrant pre-mRNA splicing. Here, we discovered that T-025 functions as an orally available and potent inhibitor of Cdc2-like kinases (CLKs), evolutionally conserved kinases that facilitate exon recognition in the splicing machinery. Treatment with T-025 reduced CLK-dependent phosphorylation, resulting in the induction of skipped exons, cell death, and growth suppression in vitro and in vivo Further, through growth inhibitory characterization, we identified high CLK2 expression or MYC amplification as a sensitive-associated biomarker of T-025. Mechanistically, the level of CLK2 expression correlated with the magnitude of global skipped exons in response to T-025 treatment. MYC activation, which altered pre-mRNA splicing without the transcriptional regulation of CLKs, rendered cancer cells vulnerable to CLK inhibitors with synergistic cell death. Finally, we demonstrated in vivo anti-tumor efficacy of T-025 in an allograft model of spontaneous, MYC-driven breast cancer, at well-tolerated dosage. Collectively, our results suggest that the novel CLK inhibitor could have therapeutic benefits, especially for MYC-driven cancer patients.
Collapse
Affiliation(s)
- Kenichi Iwai
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company, Limited, Fujisawa, Japan
| | - Masahiro Yaguchi
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company, Limited, Fujisawa, Japan
| | - Kazuho Nishimura
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company, Limited, Fujisawa, Japan
| | - Yukiko Yamamoto
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company, Limited, Fujisawa, Japan
| | - Toshiya Tamura
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company, Limited, Fujisawa, Japan
| | - Daisuke Nakata
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company, Limited, Fujisawa, Japan
| | - Ryo Dairiki
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company, Limited, Fujisawa, Japan
| | - Yoichi Kawakita
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company, Limited, Fujisawa, Japan
| | - Ryo Mizojiri
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company, Limited, Fujisawa, Japan
| | - Yoshiteru Ito
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company, Limited, Fujisawa, Japan
| | - Moriteru Asano
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company, Limited, Fujisawa, Japan
| | - Hironobu Maezaki
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company, Limited, Fujisawa, Japan
| | - Yusuke Nakayama
- Integrated Technology Research Laboratories, Takeda Pharmaceutical Company, Limited, Fujisawa, Japan
| | - Misato Kaishima
- Integrated Technology Research Laboratories, Takeda Pharmaceutical Company, Limited, Fujisawa, Japan
| | - Kozo Hayashi
- Integrated Technology Research Laboratories, Takeda Pharmaceutical Company, Limited, Fujisawa, Japan
| | - Mika Teratani
- Integrated Technology Research Laboratories, Takeda Pharmaceutical Company, Limited, Fujisawa, Japan
| | - Shuichi Miyakawa
- Biomolecular Research Laboratories, Takeda Pharmaceutical Company, Limited, Fujisawa, Japan
| | - Misa Iwatani
- Biomolecular Research Laboratories, Takeda Pharmaceutical Company, Limited, Fujisawa, Japan
| | - Maki Miyamoto
- Drug Metabolism & Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company, Limited, Fujisawa, Japan
| | - Michael G Klein
- Department of Structural Biology, Takeda California Inc., San Diego, CA, USA
| | - Wes Lane
- Department of Structural Biology, Takeda California Inc., San Diego, CA, USA
| | - Gyorgy Snell
- Department of Structural Biology, Takeda California Inc., San Diego, CA, USA
| | - Richard Tjhen
- Department of Structural Biology, Takeda California Inc., San Diego, CA, USA
| | - Xingyue He
- Oncology Drug Discovery Unit, Takeda Pharmaceuticals International Co., Cambridge, MA, USA
| | - Sai Pulukuri
- Oncology Drug Discovery Unit, Takeda Pharmaceuticals International Co., Cambridge, MA, USA
| | - Toshiyuki Nomura
- Oncology Drug Discovery Unit, Takeda Pharmaceutical Company, Limited, Fujisawa, Japan
| |
Collapse
|
4
|
Rujirachaivej P, Siriboonpiputtana T, Rerkamnuaychoke B, Magmuang S, Chareonsirisuthigul T, Boonsakan P, Petvises S, Sirirat T, Niparuck P, Chuncharunee S. The Frequency of SF3B1 Mutations in Thai Patients with Myelodysplastic Syndrome. Asian Pac J Cancer Prev 2018; 19:1825-1831. [PMID: 30049194 PMCID: PMC6165635 DOI: 10.22034/apjcp.2018.19.7.1825] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
Genetic mutations in genes encoding critical component of RNA splicing machinery including SF3B1 are frequently identified and recognized as the pathogenesis in the development of myelodysplatic syndrome (MDS). In this study, PCR sequencings specific for SF3B1 exon 13, 14, 15, and 16 were performed to analyse genomic DNA isolated from bone marrow samples of 72 newly diagnosed MDS patients. We found that 10 of 72 (14%) patients harbor SF3B1 missense mutations including E622D (1/72), R625C/G (2/72), H662Q (1/72), K666T (1/72), K700E (4/72) and G740E (1/72), respectively. Mutations were predominantly located on exon 14 and 15 of SF3B1 coding sequence. Interestingly, patients with SF3B1 mutations exhibited higher platelet counts (195×109/L VS. 140×109/L, p-value = 0.025) as well as lower hemoglobin levels (81 g/L VS. 92 g/L, p-value = 0.009) and associated with ring sideroblast phenotype (p-value < 0.001) when compared with patients without the SF3B1 mutation. In summary, we reported the frequency of SF3B1 mutations in Thai patients with different subtypes of MDS. SF3B1 mutations were predominantly occurred in MDS-RS and considered as favourable prognosis value. This study further highlighted the clinical important of SF3B1 mutations analysis for the classification of MDS.
Collapse
Affiliation(s)
- Punchita Rujirachaivej
- Division of Hematology, Clinical Pathology Laboratory, HRH Princess Maha Chakri Sirindhorn Medical Center, Nakhon, Nayok,Thailand.
| | | | | | | | | | | | | | | | | | | |
Collapse
|